The plasma fractionation market is projected to reach USD 34.9 billion by 2024 from USD 25.4 billion in 2019, at a CAGR of 6.6% during the forecast period. The plasma fractionation market is largely driven by the growing use of immunoglobulins in various therapeutic areas, increase in plasma collection (and the number of plasma collection centers), and the increasing use of alpha-1-antitrypsin. However, the high cost of plasma products, limited reimbursements, and the emergence of recombinant alternatives are expected to restrain the growth of this market during the forecast period.
North America dominated the plasma fractionation market in 2018; this trend is expected to continue during the forecast period.
Geographically, the plasma fractionation market has been studied for North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America is expected to dominate the plasma fractionation market during the forecast period. Growth in North America is primarily driven by the growing use of immunoglobulin in various therapeutic areas, growing geriatric population, and the increasing prevalence of respiratory diseases and AATD.
Recent Developments
-In January 2019, Takeda Pharmaceutical Company Limited (Japan), a global biopharmaceutical company acquired Shire, increasing its geographic footprint and global customer base.
In September 2018, Grifols launched GamaSTAN immune globulin (human) for hepatitis A virus (HAV) and measles postexposure prophylaxis, and Prolastin-C Liquid [alpha-1 proteinase inhibitor, liquid] for the treatment of alpha-1 antitrypsin deficiency
-In September 2018, Octapharma invested USD 25 million (Euro 21 million) in a new multi-function facility in Springe, Germany, that will have a new production line for human normal immunoglobulin panzyga, alongside with human albumi and albunorm.
-In August 2018, Grifols acquired Biotest US Corporation, a subsidiary of Biotest (Germany), to expand its plasma collection network with the addition of 24 Biotest centers in the US
-In February 2018, Guizhou Taibang Biological Products Co. Ltd., a wholly-owned subsidiary of China Biologic Products Organization, received approval from the Hainan Provincial Health and Family Planning Commission to build a new plasma collection station in Hainan Province.
Press Release : https://www.marketsandmarkets.com/PressReleases/plasma-fractionation.asp
North America dominated the plasma fractionation market in 2018; this trend is expected to continue during the forecast period.
Geographically, the plasma fractionation market has been studied for North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America is expected to dominate the plasma fractionation market during the forecast period. Growth in North America is primarily driven by the growing use of immunoglobulin in various therapeutic areas, growing geriatric population, and the increasing prevalence of respiratory diseases and AATD.
Recent Developments
-In January 2019, Takeda Pharmaceutical Company Limited (Japan), a global biopharmaceutical company acquired Shire, increasing its geographic footprint and global customer base.
In September 2018, Grifols launched GamaSTAN immune globulin (human) for hepatitis A virus (HAV) and measles postexposure prophylaxis, and Prolastin-C Liquid [alpha-1 proteinase inhibitor, liquid] for the treatment of alpha-1 antitrypsin deficiency
-In September 2018, Octapharma invested USD 25 million (Euro 21 million) in a new multi-function facility in Springe, Germany, that will have a new production line for human normal immunoglobulin panzyga, alongside with human albumi and albunorm.
-In August 2018, Grifols acquired Biotest US Corporation, a subsidiary of Biotest (Germany), to expand its plasma collection network with the addition of 24 Biotest centers in the US
-In February 2018, Guizhou Taibang Biological Products Co. Ltd., a wholly-owned subsidiary of China Biologic Products Organization, received approval from the Hainan Provincial Health and Family Planning Commission to build a new plasma collection station in Hainan Province.
Press Release : https://www.marketsandmarkets.com/PressReleases/plasma-fractionation.asp
Comments
Post a Comment